<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240889</url>
  </required_header>
  <id_info>
    <org_study_id>10-15912</org_study_id>
    <nct_id>NCT01240889</nct_id>
  </id_info>
  <brief_title>Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*</brief_title>
  <acronym>Roche</acronym>
  <official_title>Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Creighton University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a randomized, double blind, placebo-controlled, parallel group study and
      will include subjects with ragweed-induced seasonal allergic rhinitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this proposal is to assess the ability of an intranasal corticosteroid,
      fluticasone, and montelukast to affect the upper airway and systemic physiologic, biologic
      and clinical parameters occurring after an early and late upper airway allergic response to
      ragweed in ragweed allergic rhiniticsThe assessment of early allergy responses in the nose
      has been fairly well established in our laboratory and we will use methods detailed in
      previous publications (21, 23 24). One potential challenge will be to sample upper airway
      mediators and cytokines without affecting clinical parameters such as symptom scores and
      acoustic rhinometry readings. Moreover, we will need to sample at time points throughout six
      or more hours in order to accurately determine the effects on late phase allergic responses.
      Nasal filter paper sampling is a technique that we are currently engaged in using, and we
      will work with Roche to elute the samples and measure multiple mediators and cytokines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of nasal allergen challenges on biomarkers</measure>
    <time_frame>December 2011</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>montelukast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>luekotriene inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasal steroid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <description>nasal spray</description>
    <arm_group_label>montelukast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticason</intervention_name>
    <description>2 sprays per day in each nostril</description>
    <arm_group_label>Fluticasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 19-60 years.

          -  Females of child bearing potential must use appropriate birth control throughout the
             study and urine pregnancy tests must be negative prior to dosing at each study visit.

          -  Subjects with a documented history of ragweed-induced seasonal allergic rhinitis
             requiring pharmacotherapy during the preceding 2 allergen seasons.

          -  Subjects with a positive skin prick test to short ragweed (Amb a 1) extract, defined
             as &gt;3mm wheal larger than saline control

          -  Subjects spirometry FEV1 must be &gt; 80% predicted prior to each allergen challenge

          -  Subjects average post diluents nasal congestion score must be &lt; 1 at admission for
             each study visit

        Exclusion Criteria:

          -  Subjects with evidence or history of clinically significant medical illnesses other
             than changes related to allergic rhinitis. Subjects with some stable chronic medical
             conditions not expected to interfere with the conduct or safety of the study may be
             eligible to participate based on the investigator's discretion.

          -  Subjects with a history of asthma or urticaria, or a screening FEV1 prior to allergen
             challenge of &lt;80% of predicted. in FEV1 compared to pre-diluent FEV1 baseline at
             either screening visit.

          -  Subjects with significant nasal deformity, recent nasal surgery nasal polyps or
             chronic rhinosinusitis.

          -  Subjects who have smoked in the last 6 months or have a history of &gt;10 pack years.

          -  Subjects who are taking or have taken restricted concomitant medications that could
             confound the safety or efficacy assessments including those shown below.

          -  Subjects who have history or evidence of alcohol or drug abuse.

          -  Subjects exposed to cat and have a positive skin test to cat.

          -  Subjects that have a positive skin test to dust mite (D pteronyssinus/ D farinae)
             requiring pharmacotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas B Casale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creighton University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, AÃ¯t-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63 Suppl 86:8-160. doi: 10.1111/j.1398-9995.2007.01620.x. Review.</citation>
    <PMID>18331513</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <last_update_submitted>October 8, 2012</last_update_submitted>
  <last_update_submitted_qc>October 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2012</last_update_posted>
  <responsible_party>
    <name_title>Thomas B. Casasle, MD</name_title>
    <organization>Creighton University</organization>
  </responsible_party>
  <keyword>Ragweed allergies</keyword>
  <keyword>acoustic rhinometry</keyword>
  <keyword>nasal allergen challenge</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 12, 2012</submitted>
    <returned>January 17, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

